Molecular genotyping can improve lung cancer outcomes, recent research showed. A recent study showed that undergoing molecular genotyping before receiving ...

Undergoing treatment for a myeloproliferative neoplasm (MPN) can be extremely lonely, so it is beneficial to have a support system throughout the process, ...

The Food and Drug Administration (FDA) has accepted and granted priority review for the biologics license application for patritumab deruxtecan to treat ...

Tarlatamab showed promise in treating small-cell lung cancer. Tarlatamab, an immunotherapy drug, was shown to improve objective response rate (percentage of ...

It’s bad and probably helps cancer develop, it’s bad and probably makes symptoms worse and it’s bad and can lead to a lot of health issues (cancer and ...

The Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SLS009, a CDK9 inhibitor, for the treatment of patients with ...

Years ago, when Dr. Shamim Salman started treating patients with myeloproliferative neoplasms (MPNs), she, unfortunately saw many patients die from the ...

Patients with EGFRexon 20 insertion-positive non-small cell lung cancer experienced antitumor activity after receiving Gilotrif plus Erbitux, according to ...

I had started turning my health around, which was a blessing, and yet I also felt unsettled by not knowing what to do next. There wasn’t much of a plan in ...

The study authors determined that the 12-month PFS was 86.8% in the Retevmo group and 65.7% in the control group.Treatment with Retevmo (selpercatinib) ...